IP Library › Granted Patent US 12,396,959
Granted Patent B2
US 12,396,959 · App. 17/580,988 · Granted Aug 26, 2025

Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular drug delivery

Inventors: Morgan V. Fedorchak (Wexford, PA); Steven R. Little (Allison Park, PA); Joel S. Schuman (Pittsburgh, PA); Anthony Cugini (Pittsburgh, PA)
Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
A61K9/5021A61K9/0048A61K9/0051A61K9/06A61K9/10A61K9/5031A61K31/498A61K47/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,396,959
App. No.
17/580,988
Granted
Aug 26, 2025
Kind
B2
Abstract

A method for sustained delivery of an agent to an ocular organ in a subject, comprising topically delivering to the ocular surface a liquid thermoresponsive hydrogel comprising agent-loaded polymer microparticles, wherein the agent is sustainably released for a period of at least five days.

Claims (21)

1. A liquid composition for ocular delivery of an agent to a subject, wherein said composition comprises agent-loaded polymer microparticles dispersed within a hydrogel comprising poly (n-isopropyl acrylamide), wherein the agent is an agent for treating an ocular condition, wherein said hydrogel comprises poly (ethylene glycol) and lacks polyethylene glycol diacrylate, wherein the composition is configured to form in situ a gelled, sustained release film structure having a thickness of 10 μm to 1000 μm retained on the lower fornix of an eye in the subject and is configured for sustained topical ocular release of the agent for a period of at least thirty days, and wherein the agent is travoprost, bimatoprost, latanoprost, unoprostine, methazolamide, timolol, levobunalol, carteolol, metipranolol, betaxolol, brimonidine, apraclonidine, pilocarpine, epinephrine, dipivefrin, carbachol, acetazolamide, dorzolamide, brinzolamide, or a pharmaceutically acceptable salt or ester thereof.

2. The composition of claim 1 , wherein the liquid composition is in the form of an eye drop that can be self-administered by the subject.

3. The composition of claim 1 , wherein the agent is an agent that lowers intraocular pressure, the microparticles are biodegradable, and the hydrogel is not biodegradable.

4. The composition of claim 1 , wherein the agent-loaded polymer microparticles have a volume average diameter of 1 to 10 μm.

5. The composition of claim 1 , wherein the polymer microparticles comprise poly glycolide, poly lactic acid, poly (lactic-co-glycolic acid), alginate, polycaprolactone, cellulose, dextran, chitosan, or a combination thereof.

6. The composition of claim 1 , wherein the agent is encapsulated in the polymer microparticles.

7. The composition of claim 1 , wherein the agent is brimonidine or a pharmaceutically acceptable salt or ester thereof.

8. The composition of claim 1 , wherein the ocular condition is glaucoma, chronic dry eye, keratitis, post-operative inflammation, conjunctivitis, bacterial infection, or fungal infection.

9. The composition of claim 1 , wherein the ocular condition is glaucoma.

10. The composition of claim 1 , wherein the composition is configured to release the agent in an amount from 1 to 10 μg per day for a period of time of at least five days.

11. The composition of claim 1 , wherein the sustained topical ocular release provides a rate of release that does not vary by more than 10% over a period of time of at least five days.

12. The composition of claim 1 , wherein the sustained topical ocular release provides a rate of release that does not vary by more than 20% over a period of time of at least five days.

13. The composition of claim 1 , wherein the agent manages elevated intraocular pressure in the eye.

14. The composition of claim 1 , wherein the agent is brimonidine tartrate.

15. The composition of claim 1 , wherein the agent-loaded polymer microparticles are suspended in the hydrogel.

16. The composition of claim 1 , wherein the film structure has a thickness of 100 μm to 300 μm.

17. The composition of claim 1 , wherein the film structure conforms to the shape of the lower fornix.

18. The composition of claim 1 , wherein the film structure is opaque.

19. The composition of claim 1 , wherein the film structure is passively retained on the lower fornix of the eye.

20. The composition of claim 1 , wherein said hydrogel is opaque.

21. The composition of claim 1 , wherein said hydrogel comprises chitosan.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2022
From: FEDORCHAK, MORGAN V.; LITTLE, STEVEN R.; SCHUMAN, JOEL S.; CUGINI, ANTHONY
To: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 058888/0326 →
Continuity (3)
Division 14772758
Provisional Application 61773076 · Mar 5, 2013
Related Publication 20220211632A1 · Jul 7, 2022
References Cited (124)
US 5837226A · Jungherr et al. · 1998 [cited by applicant]
US 6264971B1 · Darougar et al. · 2001 [cited by applicant]
US 6656460B2 · Benita et al. · 2003 [cited by applicant]
US 7060299B2 · Alavattam et al. · 2006 [cited by applicant]
US 7589057B2 · Chang et al. · 2009 [cited by applicant]
US 8298569B2 · Philips et al. · 2012 [cited by applicant]
US 8492334B2 · Lavik et al. · 2013 [cited by applicant]
US 8980248B2 · Shoichet et al. · 2015 [cited by applicant]
US 9018006B2 · Stepkowski et al. · 2015 [cited by applicant]
US 9056045B2 · Hughes et al. · 2015 [cited by applicant]
US 9655862B2 · Mousa · 2017 [cited by applicant]
US 9757276B2 · Penhasi · 2017 [cited by applicant]
US 9937256B2 · Knipe et al. · 2018 [cited by applicant]
US 9937278B2 · Steinberg et al. · 2018 [cited by applicant]
US 10376592B2 · Acharya et al. · 2019 [cited by applicant]
US 10624865B2 · Pathak · 2020 [cited by applicant]
US 11246838B2 · Fedorchak et al. · 2022 [cited by applicant]
US 20010049369A1 · Jablonski et al. · 2001 [cited by applicant]
US 20020197300A1 · Schultz et al. · 2002 [cited by applicant]
US 20060018911A1 · Ault-Riche et al. · 2006 [cited by applicant]
US 20060173060A1 · Chang et al. · 2006 [cited by applicant]
US 20060235084A1 · Heller et al. · 2006 [cited by applicant]
US 20060246145A1 · Chang et al. · 2006 [cited by applicant]
US 20090252781A1 · Sawhney et al. · 2009 [cited by applicant]
US 20100209478A1 · Sawhney et al. · 2010 [cited by applicant]
US 20100261646A1 · Lavik et al. · 2010 [cited by applicant]
US 20110189291A1 · Yang et al. · 2011 [cited by applicant]
US 20110206773A1 · Lavik et al. · 2011 [cited by applicant]
US 20120040397A1 · Luo et al. · 2012 [cited by applicant]
US 20120148676A1 · Little · 2012 [cited by applicant]
US 20120156176A1 · Fujimoto et al. · 2012 [cited by applicant]
US 20120231072A1 · Kang-Mieler et al. · 2012 [cited by applicant]
US 20130189230A1 · Shoichet et al. · 2013 [cited by applicant]
US 20140086975A1 · Sinko et al. · 2014 [cited by applicant]
US 20140086995A1 · Ratner et al. · 2014 [cited by applicant]
US 20140271863A1 · Anderson et al. · 2014 [cited by applicant]
US 20140343413A1 · Jolck et al. · 2014 [cited by applicant]
US 20140343476A1 · Penhasi · 2014 [cited by applicant]
US 20150037422A1 · Kaplan et al. · 2015 [cited by applicant]
US 20150087671A1 · McClain et al. · 2015 [cited by applicant]
US 20150140106A1 · Mousa · 2015 [cited by applicant]
US 20150374633A1 · Fedorchak et al. · 2015 [cited by applicant]
US 20160058698A1 · Mayadunne et al. · 2016 [cited by applicant]
US 20160166504A1 · Jarrett et al. · 2016 [cited by applicant]
US 20160206741A1 · Knipe et al. · 2016 [cited by applicant]
US 20170189546A1 · Bidwell, III et al. · 2017 [cited by applicant]
US 20170348254A1 · O'Neil · 2017 [cited by applicant]
US 20190046479A1 · Pathak · 2019 [cited by applicant]
US 20190099365A1 · Fedorchak et al. · 2019 [cited by applicant]
US 20200246179A1 · Peyman · 2020 [cited by applicant]
US 20200360282A1 · Fedorchak et al. · 2020 [cited by applicant]
US 20210369649A1 · Fedorchak et al. · 2021 [cited by applicant]
US 20220202705A1 · Fedorchak et al. · 2022 [cited by applicant]
WO WO2011106702 · 2011 [cited by applicant]
WO WO2012044952 · 2012 [cited by applicant]
WO WO2012169972 · 2012 [cited by applicant]
WO WO2014074823 · 2014 [cited by applicant]
WO WO2014138085 · 2014 [cited by applicant]
WO WO2015001087 · 2015 [cited by applicant]
WO WO2017165449 · 2017 [cited by applicant]
WO WO2018206749 · 2018 [cited by applicant]
Park, An Anti-angiogenic Reverse Thermal Gel as a Drug-Delivery System for Age-Related Wet Macular Degeneration, Macromolecular Bioscience, 2013, 13, 464-469 (Year: 2013). [cited by examiner]
Aburahma et al., “Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro/in vivo evaluation,” AAPS PharmSciTech, Dec. 2011, 12(4):1335-1347. [cited by applicant]
Babiuch, retrieved from the retinal physician website: www.retinalphysician.com/issues/2017/june-2017/ new-monoclonal-antibody-treatments-in-retina on Aug. 19, 2019, 4 pages. [cited by applicant]
Bald et al., “2-Chloro-1-Methylquinolinium Tetrafluoroborate as an Effective and Thiol Specific UV-Tagging Reagent for Liquid Chromatography,” J. Liq. Chromatogr. Relat. Technologies, 2001, 24(9):1323-1339. [cited by applicant]
Berge et al., “Pharmaceutical salts,” J. Pharm. Sci., 66(1):1-19, Jan. 1977. [cited by applicant]
Chang et al., “Biodegradable PLGA-based Drug Delivery Systems for Modulating Ocular Surface Disease under Experimental Murine Dry Eye,” J. Clin. Exp. Ophthamol., 2(11): 13 pages, Nov. 1, 2011. [cited by applicant]
Chen et al., “Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen,” J. Mol. Bio., 293(4):865-81, Nov. 1999. [cited by applicant]
Cui et al., “New Hydrolysis-Dependent Thermosensitive Polymer for an Injectable Degradable System,” Biomacromolecules, 8(4):1280-1286, Apr. 2007. [cited by applicant]
Derwent and Mieler, “Thermoresponsive hydrogels as a new ocular drug delivery platform to the posterior segment of the eye,” Transactions of the American Ophthalmological Society, 106:206-214, Dec. 2008. [cited by applicant]
Doiron et al., “Preparation and initial characterization of biodegradable particles containing gadolinium-DTPA contrast agent for enhanced MRI,” Proc. Nat. Acad. Sci. USA, Nov. 11, 2008, 105(45):17232-17237. [cited by applicant]
Extended European Search Report issued for European Application No. 14761105.7 on Jul. 22, 2016. [cited by applicant]
Fedorchak et al., “28-day intraocular pressure reduction with a single dose of brimonidine tartrate-loaded microspheres,” Experimental Eye Research, vol. 125, 210-216, Jun. 28, 2014. [cited by applicant]
Fedorchak et al., “28-Day Ocular Delivery of Brimonidine Tartrate from Rationally Designed Degradable Microparticles in a Rabbit Model,” presentation delivered at AIChE annual meeting Oct. 31, 2012. [cited by applicant]
Fedorchak et al., “28-Day Ocular Delivery of Brimonidine Tartrate from Rationally Designed Degradable Microparticles in a Rabbit Model,” presentation delivered at Society for Biomaterials Oct. 4, 2012. [cited by applicant]
Fedorchak et al., “Advanced Controlled Release Systems for Next Generation Ophthalmic Therapy,” presentation delivered at Gordon Research Conference Mar. 22, 2012. [cited by applicant]
Fedorchak et al., “Combating Blindness with Convenient and Comfortable Glaucoma Treatments,” presentation delivered at ARVO annual meeting May 4, 2012. [cited by applicant]
Fedorchak et al., “Combating Blindness with Convenient and Comfortable Glaucoma Treatments,” presentation delivered at McGowan Institute for Regenerative Medicine annual retreat Mar. 5, 2012. [cited by applicant]
Friedman et al., “Prevalence of open-angle glaucoma among adults in the United States,” Arch. Ophthalmol., Apr. 2004, 122(4):532-538. [cited by applicant]
Fujimoto et al., “Synthesis, Characterization and Therapeutic Efficacy of a Biodegradable, Thermoresponsive Hydrogel Designed for Application in Chronic Infarcted Myocardium,” Biomaterials, 30(26):4357-4368, Sep. 2009. [cited by applicant]
Gao et al., “A Microparticle/Hydrogel Combination Drug-Delivery System for Sustained Release of Retinoids,” Investigative Ophthamology & Visual Science, 53:10, 6314-6323, Sep. 2012. [cited by applicant]
Ghate et al., “Barriers to Glaucoma Drug Delivery,” J. Glaucoma, Mar. 2008, 17(2):147-156. [cited by applicant]
Gu et al., “Controlled release of recombinant human nerve growth factor (rhNGF) from poly [(lactic acid)-co-(glycolic acid)]microspheres for the treatment of neurodegenerative disorders,” Polymer International, 56( 10):… [cited by applicant]
Guan et al., “Protein-reactive, Thermoresponsive Copolymers With High Flexibility and Biodegradability,” Biomacromolecules, 9(4):1283-92, Apr. 2008. [cited by applicant]
Hermann et al., “Electronic compliance monitoring of topical treatment after ophthalmic surgery,” Int. Ophthalmol., Apr. 7, 2010, 30:385-390. [cited by applicant]
Hu et al., “Controlled Release Bevacizumab in Thermoresponsive Hydrogel Found to Inhibit Angiogenesis,” Biomed. Mater. Eng., 24:1941-50, 2014. [cited by applicant]
Ibrahim et al., “Novel Topical Ophthalmic Formulations for Management of Glaucoma,” Pharmaceutical Research, 30(11): 2818-2831, Nov. 15, 2013. [cited by applicant]
International Search Report issued in PCT/US2014/020355 mailed Jul. 10, 2014, 5 pages. [cited by applicant]
Jimenez et al., “A sustained release cysteamine microsphere/thermoresponsive gel eyedrop for corneal cystinosis improves drug stability,” Drug Deliv. Transl. Research, Feb. 4, 2021, 11(5):2224-2238. [cited by applicant]
Karamanos et al., “Development of an HPLC method for determining the alpha2-adrenergic receptor agonist brimonidine in blood serum and aqueous humor of the eye,” Biomed. Chromatogr., 1999, 13:86-88. [cited by applicant]
Knight et al., “Sustained drug delivery in glaucoma,” Current Opinion in Ophthamology, 25(2): 112-117, Mar. 2014. [cited by applicant]
Kusmierek et al., “Measurement of reduced and total mercaptamine in urine using liquid chromatography with ultraviolet detection,” Biomed. Chromatography, Jan. 18, 2008, 22(4):441-445. [cited by applicant]
Lambiase et al., “Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma,” PNAS, 106(32): 13469-13474, Aug. 11, 2009. [cited by applicant]
Lee and Vernon, “In Situ-Gelling, Erodible N-isopropylacrylamide Copolymers,” Macromol. Biosci., 5(7):629-635, Jul. 2005. [cited by applicant]
MacCallum et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography,” J. Mol. Biol., 262(5):732-45, Oct. 1996. [cited by applicant]
Na et al., Langmuir 2010; 26:11165-11169. [cited by applicant]
Nanjawade et al., “In situ-forming hydrogels for sustained ophthalmic drug delivery,” J. Control Release., 122(2):119-34, Sep. 2007. [cited by applicant]
Nussenblatt et al. Retina, 2013; 30:1579-1587. doi:10.1097/IAE.0b013e3181e7878e. [cited by applicant]
Pascual-Camps et al. J. Ophthal. Inflam. Infect. 2014; 4:26. www.joii-journal.conn/content/4/1/26. [cited by applicant]
Pescina et al., “Effect of pH and penetration enhancers on cysteamine stability and trans-corneal transport,” Eur. J. Pharm. Biopharmaceutics, Oct. 2016, 107: 171-179. [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. U.S.A., 79(6):1979-1983, Mar. 1982. [cited by applicant]
Sánchez et al., “Development of biodegradable microspheres and nanospheres for the controlled release of cyclosporin A,” Int. J. Pharmaceutics, Oct. 15, 1993, 99(2-3):263-273. [cited by applicant]
Shanbhag et al., “Macrophage/particle interactions: effect of size, composition and surface area,” J. Biomed. Mater. Res., Jan. 1994, 28(1):81-90. [cited by applicant]
Turturro et al., “The effects of cross-linked thermo-responsive PNIPAAm-based hydrogel injection on retinal function,” Biomaterials, 32(14):3620-6, May 2011. [cited by applicant]
Wang et al., “Novel Thermosensitive Hydrogel Injection Inhibits Post-Infarct Ventricle Remodelling,” Eur. J. Heart Fail, 11(1):14-19, Jan. 2009. [cited by applicant]
Wang et al., “Synthesis, Characterization and Surface Modification of Low Moduli Poly(ether Carbonate Urethane)ureas for Soft Tissue Engineering,” Acta. Biomater., 5(8):2901-12, Oct. 2009. [cited by applicant]
Wang et al., “The nerve growth factor signaling and its potential as therapeutic target for glaucoma,” BioMed Research International, Aug. 31, 2014. [cited by applicant]
Wikipedia.org [online], “Cysteamine,” dated Sep. 7, 2018, retrieved from URL<https://en.wikipedia.org/w/index.php?title=Cysteamine&oldid=858431558>, 5 pages. [cited by applicant]
Wikipedia.org [online], “Freeze drying,” dated Nov. 6, 2018, retrieved from URL<https://en.wikipedia.org/w/index.php?title=Freeze-drying&oldid=924871987>, 12 pages. [cited by applicant]
Wu et al., “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues,” J. Mol. Biol., 294(1):151-162, Nov. 1999. [cited by applicant]
Wu et al., “Toward the development of partially biodegradable and injectable thermoresponsive hydrogels for potential biomedical applications,” ACS Appl. Mater. Interf., 1(2):312-327, Feb. 2009. [cited by applicant]
Xu et al. Macromolecules, 2007; 40:9103-9110. [cited by applicant]
Yang et al., “Hybrid Dendrimer Hydrogel/PLGA Nanoparticle Platform Sustains Drug Delivery for One Week and Antiglaucoma Effects for Four Days Following One-Time Topical Administration,” ACS Nano, 6(9): 7595-7606, Aug. 9… [cited by applicant]
Zhang and Zhuo, “Synthesis and in vitro drug release behavior of amphiphilic triblock copolymer nanoparticles based on poly (ethylene glycol) and polycaprolactone,” Biomaterials, 26(33):6736-42, Nov. 2005. [cited by applicant]
Zhang et al., “Absolute quantification of poly(dl-lactide-co-glycolide) in microspheres using quantitative 1H NMR spectroscopy,” J. Pharm. Biomed. Analysis, Nov. 30, 2017, 146:273-278. [cited by applicant]
Zweers et al., “Release of anti-restenosis drugs from poly(ethylene oxide)-poly(dl-lactic-co-glycolic acid) nanoparticles,” J. Control. Release, Sep. 12, 2006, 114(3):317-324. [cited by applicant]
U.S. Appl. No. 17/281,647, filed Mar. 31, 2021, Morgan Virginia Fedorchak, Published as U.S. Patent Application Publication No. 2021/0369649. [cited by applicant]
U.S. Appl. No. 17/577,816, filed Jan. 18, 2022, Morgan Virginia Fedorchak, Pending. [cited by applicant]
Shams et al., “Treatment of corneal cystine crystal accumulation in patients with cystinosis,” Clin. Ophthalmol, Oct. 2014, 8:2077-2084. [cited by applicant]
Bhagav et al., “Sustained release ocular inserts of brimonidine tartrate for better treatment in open-angle glaucoma,” Drug Deliv. Transl. Res., Apr. 2011, 1(2):161-174. [cited by applicant]
Fedorchak et al., “Long Term Glaucoma Drug Delivery Using a Topically Retained Gel/Microsphere Eye Drop,” Sci. Rep., Aug. 2017, 7:8639. [cited by applicant]
Luaces-Rodriguez et al., “Cysteamine polysaccharide hydrogels: Study of extended ocular delivery and biopermanence time by PET imaging,” Int. J. Pharm., Aug. 2017, 528(1-2):714-722. [cited by applicant]
Wan et al., “Modulating protein release profiles by incorporating hyaluronic acid into PLGA microparticles via a spray dryer equipped with a 3-fluid nozzle,” Pharm. Res., Nov. 2014, 31(11):2940-2951. [cited by applicant]
Maren et al., “Ocular pharmacology of methazolamide analogs: distribution in the eye and effects on pressure after topical application,” J. Pharmacol. Exp. Ther., Apr. 1987, 241(1):56-63. [cited by applicant]